MARKET

GRFS

GRFS

Grifols S A
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.20
+0.13
+0.99%
After Hours: 13.20 0 0.00% 16:00 05/26 EDT
OPEN
13.15
PREV CLOSE
13.07
HIGH
13.25
LOW
13.12
VOLUME
750.32K
TURNOVER
0
52 WEEK HIGH
19.07
52 WEEK LOW
10.10
MARKET CAP
3.38B
P/E (TTM)
43.28
1D
5D
1M
3M
1Y
5Y
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announce...
GlobeNewswire · 05/19 15:39
Grifols Unit Says Research Shows Machine Learning Potential in Improving Drug Discovery
MT Newswires · 05/19 12:38
Deutsche Bank’s Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced that the presentations from the May 10th and 11th Depositary Receipts Virtual Investor Conference (“dbVIC”) are now available for on-demand viewing. The event featured presentations f...
GlobeNewswire · 05/12 13:54
Grifols stock slumps on Spain's stock exchange paring gains seen after Q1 results
Spanish biotech Grifols (NASDAQ:GRFS) stock fell ~8% May 9 on Spain's stock exchange BME, where it trades under the symbol GRF, giving up most of the gains following its Q1
Seekingalpha · 05/09 09:49
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022
DB DB Logo NEW YORK, May 08, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, May 10 and Wednesday, May 11, featuring live webcast presentations from internation...
GlobeNewswire · 05/09 00:30
ChemoCentryx, iRhythm top healthcare gainers; Joint, Endo lead losers' pack
Gainers: ChemoCentryx (CCXI) +19%. iRhythm Technologies (IRTC) +16%. Jounce Therapeutics (JNCE) +15%. Grifols (GRFS) +9%. Sensus Healthcare (SRTS) +8%. Losers: Joint (JYNT) -46%. Endo International (ENDP) -34%. Guardant Health (GH) -26%. Gain Therapeutics ...
Seekingalpha · 05/06 14:05
MFGP, API and AQST among pre market gainers
Sonoma Pharmaceuticals SNOA +47% on EPA approval of Nanocyn as hospital-grade disinfectant. Field Trip Health (FTRP) +23%. Harbor Custom Development (HCDI) +18%. Western Digital WDC +12% as activist Elliott calls for separation of flash
Seekingalpha · 05/03 12:31
Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2021 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 29, 2022. Grifols' Annual Report on Form 20-F inclu...
PR Newswire · 04/29 18:00
More
No Data
Learn about the latest financial forecast of GRFS. Analyze the recent business situations of Grifols S A through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
50.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GRFS stock price target is 18.11 with a high estimate of 23.15 and a low estimate of 13.06.
High23.15
Average18.11
Low13.06
Current 13.20
EPS
Actual
Estimate
0.100.190.280.38
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 249
Institutional Holdings: 112.28M
% Owned: 43.80%
Shares Outstanding: 256.35M
TypeInstitutionsShares
Increased
46
9.22M
New
21
1.86M
Decreased
44
9.02M
Sold Out
20
1.84M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.31%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman
Victor Grifols Roura
Co-Chief Executive Officer/Executive Director
Victor Grifols Deu
Co-Chief Executive Officer/Executive Director
Raimon Grifols Roura
Non-Executive Vice Chairman
Thomas Glanzmann
Chief Financial Officer
Alfredo Arroyo Guerra
Corporate Executive
Joel Abelson
Corporate Executive
David Dew
Corporate Executive
Antoni Fages
Corporate Executive
Alberto Grifols Roura
Corporate Executive
Chris Healey
Corporate Executive
Eduardo Raimundo Herrero Jimenez
Corporate Executive
Robert Jagt
Corporate Executive
Antonio Martinez Martinez
Corporate Executive
Miguel Pascual Montblanch
Corporate Executive
Sergio Roura Adell
Chief Human Resource Officer
Montserrat Gaja
Chief Technology Officer/Chief Information Officer
Javier Sueiras Gil
Chief Scientific Officer
Albert Coma-Cros
Vice President/Director of Investor Relations
Nuria Pascual Lapena
Vice President
Matthew Murawski
Vice President
Fernando Sebastian Rodriguez Haro
General Counsel
David Bell
Other
Vicente Blanquer Torre
Other
Daniel Fleta Coit
Other
Lafmin Morgan
Other
Maria Rione
Secretary
Nuria Martin Barnes
Assistant Secretary/Director
Tomas Daga Gelabert
Lead Director/Independent Director
Carina Lazaro
Independent Director
Inigo Sanchez Asiain Mardones
Independent Director
James Costos
Independent Director
Enriqueta Felip Font
Independent Director
Steven Mayer
Independent Director
Marla Salmon
Independent Director
Belen Villalonga Morenes
No Data
No Data
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Webull offers kinds of Grifols SA - ADR stock information, including NASDAQ:GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.